Effects of piroxicam-beta-cyclodextrin sachets on abnormal postural sway in patients with chronic low back pain

Abstract

Piroxicam-beta-cyclodextrin (PBC) sachet may have greater improvement in the treatment of chronic LBP and possess the extended effects on postural abnormality relevant to chronic LBP.

Impairment of static upright posture in subjects with undifferentiated arthritis in sacroiliac joint in conjunction with elevation of streptococcal serology

“…The protocol for sway platform testing was the same as before [5,6,8]. In brief, subjects were asked to stand motionless on a ground level platform for 60 seconds with bare feet, first with their eyes open and again with their eyes closed.…”

“…The clinical assessment of sway is the single best predictor of static posture stability, which is eligible for quantitative measurement in many situations, such as LBP, spina bifida occulta, or ethanol exposure [5,6,8,9,28].…”

Evaluation of piroxicam-β-cyclodextrin as a preemptive analgesic in functional endoscopic sinus surgery

“…PBCD was regarded as an effective analgesic at doses of 20 and 40 mg/day. Preemptive administration of PBCD effectively reduced morphine consumption, and especially the 40-mg dose was found to be more effective than the 20-mg dose and than the treatment administered to the control group during the postoperative period (11)(12)(13)(14)(15)(16)(17)(18).…”

“…No reports were identified in the literature in PubMed, from 1990 to 2009, on the use of PBCD for postoperative analgesia after endoscopic sinus surgery, although it has been shown to be effective in reducing pain in other situations (11)(12)(13)(14)(15)(16)(17)(18). NSAIDs are gaining popularity in the management of pain associated with ambulatory surgery.…”

Inter-molecular physiochemical characterization for etodolac-hydroxypropyl-β-cyclodextrin polymeric systems in solid and liquid state

“…Recently various studies involving inclusion complexation phenomena have been reported for new generation NSAIDs which are almost insoluble in water, primarily to enhance the oral bioavailability and dissolution behavior [7][8][9]. EDC((RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano [3,4-b]indol-1-yl)acetic acid) is a newer NSAID belonging to the arylalkanoic class, which…”